VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | The potential of inhibiting SUMOylation as a therapeutic strategy in multiple myeloma

Li Du, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, highlights the potential of inhibition sumoylation to increase the cytotoxicity of existing anti-myeloma therapies. Dr Du explains that previous experiments have shown that inhibiting SUMO E1 potentiates the effect of lenalidomide and dexamethasone and immunotherapies. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter